Patricia Carr sold $806k of JAZZ
SVP, Chief Accounting Officer at Jazz Pharmaceuticals plc. 5,586 shares at an average of $144.26, traded Feb 27, 2025, filed Mar 3, 2025.
Score components
- +15RoleOfficer
- +22Trade size$806k at market
- +10Share of holdings soldSold 44% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001765581-25-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2025 | MOption exercise Ordinary Shares | +4,500 | $113.10 | $509k | 12,737 | Mar 3, 2025 |
| Feb 27, 2025 | SOpen-market sale Ordinary Shares | -4,500 | $144.42 | $650k | 8,237 | Mar 3, 2025 |
| Feb 27, 2025 | MOption exercise Ordinary Shares | +313 | $123.36 | $39k | 8,550 | Mar 3, 2025 |
| Feb 27, 2025 | SOpen-market sale Ordinary Shares | -313 | $144.42 | $45k | 8,237 | Mar 3, 2025 |
| Feb 27, 2025 | DDisposition to issuer Ordinary Shares | -371 | $142.43 | $53k | 7,866 | Mar 3, 2025 |
| Feb 27, 2025 | DDisposition to issuer Ordinary Shares | -497 | $142.43 | $71k | 7,369 | Mar 3, 2025 |
| Feb 27, 2025 | AGrant or award Ordinary Shares | +2,889 | $0.00 | $0 | 10,258 | Mar 3, 2025 |
| Feb 28, 2025 | SOpen-market sale Ordinary Shares | -773 | $143.30 | $111k | 9,485 | Mar 3, 2025 |
| Feb 27, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -4,500 | $0.00 | $0 | 0 | Mar 3, 2025 |
| Feb 27, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -313 | $0.00 | $0 | 0 | Mar 3, 2025 |
Related signals
Other insiders at Jazz Pharmaceuticals plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $473k 2,000 shares | -1% | |
| 28Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $289k 1,200 shares | -2% | |
| 38Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $486k 2,000 shares | -1% | |
| 45Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 51Moderate | Jazz Pharmaceuticals plc | Mary Elizabeth Henderson SVP, Technical Operations | $379k 2,238 shares | -10% | |
| 57Moderate | Jazz Pharmaceuticals plc | Patricia Carr SVP, Chief Accounting Officer | $798k 4,660 shares | -65% | |
| 45Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $14M 77,500 shares | -16% | |
| 39Weak | Jazz Pharmaceuticals plc | Heather Ann McSharry director | $607k 3,415 shares | -14% | |
| 55Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $3.3M 18,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.